Rigel Pharmaceuticals Inc
RIGL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001034842
No open-market purchases or sales by Rigel Pharmaceuticals Inc insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $640.6M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:37 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M |
| Cost of revenue | $19.6M | $18.6M | $7.11M | $1.75M | $1.08M |
| Research and development | $33.3M | $23.4M | $24.5M | $60.3M | $65.2M |
| Selling, general and administrative | $115.9M | $113.1M | $105.7M | $112.5M | $91.9M |
| Operating income | $125.5M | $24.2M | -$20.5M | -$55.5M | -$12.5M |
| Interest expense | – | $7.92M | $6.87M | $3.71M | $4.86M |
| Income tax | -$245.2M | $881.0K | – | – | $605.0K |
| Net income | $367.0M | $17.5M | -$25.1M | -$58.6M | -$17.9M |
| EPS, basic | $20.40 | $0.99 | $-0.14 | $-0.34 | $-0.11 |
| EPS, diluted | $19.48 | $0.99 | $-0.14 | $-0.34 | $-0.11 |
| Weighted shares, basic | 18.0M | 17.6M | 174.0M | 172.4M | 170.5M |
| Weighted shares, diluted | 18.8M | 17.7M | 174.0M | 172.4M | 170.5M |
| Margins and growth | |||||
| Operating margin | 42.6% | 13.5% | -17.5% | -46.2% | -8.4% |
| Net margin | 124.7% | 9.8% | -21.5% | -48.7% | -12.0% |
| Revenue growth, year over year | +64.1% | +53.4% | −2.8% | −19.4% | +37.4% |
| Net income growth, year over year | +1,999.1% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $40.6M | $56.7M | $32.8M | $24.5M | $18.9M |
| Short-term investments | $114.4M | $20.6M | $24.1M | $33.7M | $106.1M |
| Accounts receivable | $51.8M | $41.6M | $30.6M | $40.3M | $15.5M |
| Inventory | $11.5M | $6.00M | $5.52M | $9.12M | $6.62M |
| Total current assets | $240.2M | $135.1M | $99.3M | $115.9M | $154.5M |
| Property, plant and equipment | $30.0K | $92.0K | $165.0K | $857.0K | $2.18M |
| Intangible assets | $24.7M | $27.1M | $13.9M | $14.9M | – |
| Total assets | $513.6M | $164.0M | $117.2M | $134.3M | $167.3M |
| Accounts payable | $7.19M | $3.34M | $7.14M | $22.5M | $3.79M |
| Total current liabilities | $99.2M | $63.3M | $53.3M | $65.2M | $63.6M |
| Long-term debt | $52.5M | $60.0M | $60.0M | $40.0M | $20.0M |
| Total liabilities | $122.1M | $160.7M | $145.9M | $147.9M | – |
| Shareholders' equity | $391.5M | $3.29M | -$28.6M | -$13.6M | $30.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | $75.7M | $31.5M | -$5.74M | -$73.8M | $5.88M |
| Capital expenditures | – | – | – | $450.0K | $627.0K |
| Free cash flow | – | – | – | -$74.2M | $5.25M |
| Depreciation and amortization | $2.42M | $2.23M | $1.24M | $998.0K | $1.16M |
| Stock-based compensation | $12.7M | $12.4M | $8.81M | $12.4M | $9.49M |
| Investing cash flow | -$92.4M | $4.13M | -$4.30M | $72.8M | -$80.0M |
| Financing cash flow | $601.0K | -$11.6M | $18.4M | $6.55M | $62.7M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 4.3% | 6.9% | 7.5% | 10.3% | 6.4% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 18.8M | +3.7% | SEC |
| Jul 30, 2026 | 18.7M | +4.1% | SEC |
| Apr 30, 2026 | 18.5M | +3.5% | SEC |
| Feb 25, 2026 | 18.5M | +3.4% | SEC |
| Oct 30, 2025 | 18.2M | +3.0% | SEC |
| Jul 31, 2025 | 17.9M | +1.9% | SEC |
| May 1, 2025 | 17.9M | −89.8% | SEC |
| Feb 25, 2025 | 17.9M | −89.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-10 in Q2 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.